Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Brian Concannon. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Brian Concannon har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:CNMD / CONMED Corporation | Director | 10 116 |
US:HAE / Haemonetics Corporation | President & CEO, Director | 39 414 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Brian Concannon. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp CNMD / CONMED Corporation - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i CNMD / CONMED Corporation. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i CNMD / CONMED Corporation. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderköp HAE / Haemonetics Corporation - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i CNMD / CONMED Corporation. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i CNMD / CONMED Corporation. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Brian Concannon som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 479 | 10 116 | 4,97 | ||||
2024-06-05 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 302 | 9 637 | 3,24 | ||||
2023-06-08 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −812 | 9 335 | −8,00 | 129,01 | −104 756 | 1 204 308 | |
2023-06-02 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 335 | 10 147 | 3,41 | ||||
2023-05-02 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −2 072 | 9 812 | −17,44 | 125,00 | −259 000 | 1 226 500 | |
2022-06-02 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 812 | 11 884 | 7,33 | ||||
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Sars (Stock Appreciation Rights) |
M - Exercise | −1 000 | 0 | −100,00 | ||||
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Sars (Stock Appreciation Rights) |
M - Exercise | −1 000 | 0 | −100,00 | ||||
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Sars (Stock Appreciation Rights) |
M - Exercise | −1 000 | 0 | −100,00 | ||||
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Options To Purchase Common Stock |
M - Exercise | −1 843 | 0 | −100,00 | ||||
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Options To Purchase Common Stock |
M - Exercise | −2 165 | 0 | −100,00 | ||||
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Options To Purchase Common Stock |
M - Exercise | −2 549 | 0 | −100,00 | ||||
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
F - Taxes | −401 | 11 072 | −3,50 | 139,03 | −55 751 | 1 539 340 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 1 000 | 11 473 | 9,55 | 55,70 | 55 700 | 639 046 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
F - Taxes | −286 | 10 473 | −2,66 | 139,03 | −39 763 | 1 456 061 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 1 000 | 10 759 | 10,25 | 39,64 | 39 640 | 426 487 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
F - Taxes | −241 | 9 759 | −2,41 | 139,03 | −33 506 | 1 356 794 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 1 000 | 10 000 | 11,11 | 33,43 | 33 430 | 334 300 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −1 843 | 9 000 | −17,00 | 135,06 | −248 916 | 1 215 540 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 1 843 | 10 843 | 20,48 | 73,94 | 136 271 | 801 731 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −2 165 | 9 000 | −19,39 | 135,08 | −292 448 | 1 215 720 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 2 165 | 11 165 | 24,06 | 79,94 | 173 070 | 892 530 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −2 549 | 9 000 | −22,07 | 135,08 | −344 319 | 1 215 720 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 2 549 | 11 549 | 28,32 | 69,03 | 175 957 | 797 227 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −200 | 9 000 | −2,17 | 137,91 | −27 582 | 1 241 190 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −4 200 | 9 200 | −31,34 | 136,96 | −575 232 | 1 260 032 | |
2022-02-04 |
|
4 | CNMD |
CONMED Corp
Common Stock |
S - Sale | −2 027 | 13 400 | −13,14 | 135,09 | −273 827 | 1 810 206 | |
2021-06-03 |
|
4 | CNMD |
CONMED Corp
Options To Purchase Common Stock |
A - Award | 865 | 865 | |||||
2021-06-03 |
|
4 | CNMD |
CONMED Corp
Rsus (restricted Stock Units) |
A - Award | 812 | 812 | |||||
2021-06-03 |
|
4 | CNMD |
CONMED Corp
Rsus (restricted Stock Units) |
M - Exercise | −1 521 | 0 | −100,00 | ||||
2021-06-03 |
|
4 | CNMD |
CONMED Corp
Common Stock |
M - Exercise | 1 521 | 15 427 | 10,94 | ||||
2020-09-14 |
|
4 | CNMD |
CONMED CORP
Common Stock |
S - Sale | −3 036 | 13 906 | −17,92 | 89,31 | −271 145 | 1 241 945 | |
2020-06-03 |
|
4 | CNMD |
CONMED CORP
Options To Purchase Common Stock |
A - Award | 1 843 | 1 843 | |||||
2020-06-03 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 1 521 | 1 521 | |||||
2020-06-03 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
M - Exercise | −1 407 | 0 | −100,00 | ||||
2020-06-03 |
|
4 | CNMD |
CONMED CORP
Common Stock |
M - Exercise | 1 407 | 16 942 | 9,06 | ||||
2019-06-04 |
|
4 | CNMD |
CONMED CORP
Options To Purchase Common Stock |
A - Award | 2 165 | 2 165 | |||||
2019-06-04 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 1 407 | 1 407 | |||||
2019-06-04 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
M - Exercise | −1 629 | 0 | −100,00 | ||||
2019-06-04 |
|
4 | CNMD |
CONMED CORP
Common Stock |
M - Exercise | 1 629 | 15 535 | 11,71 | ||||
2018-06-04 |
|
4 | CNMD |
CONMED CORP
Options To Purchase Common Stock |
A - Award | 2 549 | 2 549 | |||||
2018-06-04 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 1 629 | 1 629 | |||||
2018-06-04 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
M - Exercise | −2 167 | 0 | −100,00 | ||||
2018-06-04 |
|
4 | CNMD |
CONMED CORP
Common Stock |
M - Exercise | 2 167 | 13 906 | 18,46 | ||||
2017-06-02 |
|
4 | CNMD |
CONMED CORP
Options To Purchase Common Stock |
A - Award | 3 669 | 3 669 | 51,90 | 190 421 | 190 421 | ||
2017-06-02 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 2 167 | 2 167 | |||||
2017-06-02 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
M - Exercise | −2 739 | 0 | −100,00 | ||||
2017-06-02 |
|
4 | CNMD |
CONMED CORP
Common Stock |
M - Exercise | 2 739 | 11 739 | 30,43 | ||||
2016-06-03 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 2 739 | 2 739 | |||||
2016-06-03 |
|
4 | CNMD |
CONMED CORP
Options To Purchase Common Stock |
A - Award | 5 396 | 5 396 | |||||
2016-06-03 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
M - Exercise | −3 000 | 0 | −100,00 | ||||
2016-06-03 |
|
4 | CNMD |
CONMED CORP
Common Stock |
M - Exercise | 3 000 | 9 000 | 50,00 | ||||
2015-09-16 |
|
4 | HAE |
HAEMONETICS CORP
Non-qualified Stock Option (Right to Buy) |
M - Exercise | −6 569 | 39 414 | −14,29 | ||||
2015-09-16 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −6 569 | 147 040 | −4,28 | 35,15 | −230 900 | 5 168 456 |
2015-09-16 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 6 569 | 153 609 | 4,47 | 27,69 | 181 896 | 4 253 433 |
2015-09-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 4 761 | −50,02 | 35,63 | −169 792 | 169 650 |
2015-09-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 35,63 | −169 792 | 5 239 506 |
2015-09-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-08-18 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −6 569 | 45 983 | −12,50 | 39,28 | −258 019 | 1 806 134 |
2015-08-18 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −6 569 | 147 040 | −4,28 | 39,28 | −258 019 | 5 775 481 |
2015-08-18 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 6 569 | 153 609 | 4,47 | 27,68 | 181 863 | 4 252 665 |
2015-08-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 9 526 | −33,34 | 39,91 | −190 189 | 380 219 |
2015-08-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 39,91 | −190 189 | 5 868 925 |
2015-08-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-07-16 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −6 569 | 52 552 | −11,11 | 39,59 | −260 092 | 2 080 733 |
2015-07-16 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −6 569 | 147 040 | −4,28 | 39,59 | −260 092 | 5 821 872 |
2015-07-16 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 6 569 | 153 609 | 4,47 | 27,68 | 181 863 | 4 252 665 |
2015-07-06 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 14 291 | −25,01 | 41,28 | −196 711 | 589 968 |
2015-07-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 41,28 | −196 711 | 6 070 179 |
2015-07-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-07-02 |
|
4/A | CNMD |
CONMED CORP
Sars (Stock Appreciation Rights) |
A - Award | 1 000 | 1 000 | |||||
2015-07-02 |
|
4/A | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 3 000 | 3 000 | |||||
2015-06-17 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −6 569 | 59 121 | −10,00 | 42,51 | −279 221 | 2 512 991 |
2015-06-17 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −6 569 | 147 040 | −4,28 | 42,51 | −279 221 | 6 250 068 |
2015-06-17 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 6 569 | 153 609 | 4,47 | 27,68 | 181 863 | 4 252 665 |
2015-06-03 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
M - Exercise | −3 000 | 0 | −100,00 | ||||
2015-06-03 |
|
4 | CNMD |
CONMED CORP
Common Stock |
M - Exercise | 3 000 | 6 000 | 100,00 | ||||
2015-06-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 19 056 | −20,00 | 41,39 | −197 214 | 788 692 |
2015-06-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 41,39 | −197 214 | 6 085 706 |
2015-06-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-05-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 23 821 | −16,67 | 40,74 | −194 139 | 970 532 |
2015-05-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 40,74 | −194 139 | 5 990 807 |
2015-05-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-04-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 28 586 | −14,29 | 44,51 | −212 076 | 1 272 280 |
2015-04-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 44,51 | −212 076 | 6 544 324 |
2015-04-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-03-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 33 351 | −12,50 | 44,41 | −211 617 | 1 481 145 |
2015-03-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 44,41 | −211 617 | 6 530 164 |
2015-03-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-02-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 38 116 | −11,11 | 39,15 | −186 530 | 1 492 085 |
2015-02-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 39,15 | −186 530 | 5 756 013 |
2015-02-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2015-01-06 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 42 881 | −10,00 | 37,20 | −177 252 | 1 595 117 |
2015-01-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 37,20 | −177 252 | 5 469 697 |
2015-01-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2014-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 47 646 | −9,09 | 36,72 | −174 979 | 1 749 647 |
2014-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 36,72 | −174 979 | 5 399 573 |
2014-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2014-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 765 | 52 411 | −8,33 | 35,86 | −170 888 | 1 879 621 |
2014-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 765 | 147 040 | −3,14 | 35,86 | −170 888 | 5 273 310 |
2014-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 765 | 151 805 | 3,24 | 27,28 | 129 965 | 4 140 481 |
2014-10-29 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −3 215 | 147 040 | −2,14 | 36,22 | −116 447 | 5 325 789 |
2014-10-29 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −2 794 | 150 255 | −1,83 | 36,22 | −101 199 | 5 442 236 |
2014-10-29 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −2 188 | 153 049 | −1,41 | 35,92 | −78 593 | 5 497 520 |
2014-10-24 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −2 048 | 155 237 | −1,30 | 35,44 | −72 581 | 5 501 599 |
2014-10-24 |
|
4 | HAE |
HAEMONETICS CORP
Performance Shares |
A - Award | 53 956 | 103 956 | 107,91 | ||||
2014-10-24 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
A - Award | 119 731 | 119 731 | |||||
2014-10-24 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
A - Award | 26 978 | 157 285 | 20,70 | ||||
2014-09-15 |
|
4 | CNMD |
CONMED CORP
Sars (Stock Appreciation Rights) |
A - Award | 1 000 | 1 000 | |||||
2014-09-15 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 3 000 | 3 000 | |||||
2014-08-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 380 | 0 | −100,00 | 35,27 | −154 465 | |
2014-08-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 380 | 130 307 | −3,25 | 35,27 | −154 465 | 4 595 407 |
2014-08-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 380 | 134 687 | 3,36 | 25,54 | 111 843 | 3 439 233 |
2014-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 4 380 | −51,22 | 35,83 | −164 798 | 156 916 |
2014-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 35,83 | −164 798 | 4 668 326 |
2014-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2014-06-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 8 980 | −33,87 | 33,54 | −154 300 | 301 221 |
2014-06-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 33,54 | −154 300 | 4 370 953 |
2014-06-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2014-06-02 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
M - Exercise | −3 000 | 0 | −100,00 | ||||
2014-06-02 |
|
4 | CNMD |
CONMED CORP
Common Stock |
M - Exercise | 3 000 | 3 000 | |||||
2014-05-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 13 580 | −25,30 | 30,01 | −138 042 | 407 524 |
2014-05-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 30,01 | −138 042 | 3 910 396 |
2014-05-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2014-04-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 18 180 | −20,19 | 32,71 | −150 466 | 594 666 |
2014-04-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 32,71 | −150 466 | 4 262 329 |
2014-04-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2014-03-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 22 780 | −16,80 | 36,36 | −167 235 | 828 178 |
2014-03-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 36,36 | −167 235 | 4 737 376 |
2014-03-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2014-02-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 27 380 | −14,38 | 37,63 | −173 080 | 1 030 203 |
2014-02-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 0 | −100,00 | 37,64 | −112 916 | |
2014-02-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 130 307 | −2,25 | 37,64 | −112 916 | 4 904 586 |
2014-02-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 133 307 | 2,30 | 13,05 | 39 158 | 1 739 990 |
2014-02-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 37,63 | −173 080 | 4 902 944 |
2014-02-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2014-01-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 31 980 | −12,58 | 41,55 | −191 141 | 1 328 843 |
2014-01-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 3 000 | −50,00 | 41,63 | −124 888 | 124 888 |
2014-01-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 130 307 | −2,25 | 41,63 | −124 888 | 5 424 615 |
2014-01-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 133 307 | 2,30 | 13,05 | 39 158 | 1 739 990 |
2014-01-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 41,55 | −191 141 | 5 414 556 |
2014-01-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2013-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 36 580 | −11,17 | 42,29 | −194 548 | 1 547 078 |
2013-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 6 000 | −33,33 | 42,33 | −126 980 | 253 961 |
2013-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 130 307 | −2,25 | 42,33 | −126 980 | 5 515 478 |
2013-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 133 307 | 2,30 | 13,05 | 39 158 | 1 739 990 |
2013-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 42,29 | −194 548 | 5 511 074 |
2013-12-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2013-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −4 600 | 41 180 | −10,05 | 39,96 | −183 806 | 1 645 462 |
2013-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 9 000 | −25,00 | 39,96 | −119 881 | 359 644 |
2013-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 130 307 | −2,25 | 39,96 | −119 881 | 5 207 120 |
2013-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 133 307 | 2,30 | 13,05 | 39 158 | 1 739 990 |
2013-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −4 600 | 130 307 | −3,41 | 39,96 | −183 806 | 5 206 781 |
2013-11-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 4 600 | 134 907 | 3,53 | 25,54 | 117 461 | 3 444 850 |
2013-10-29 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −2 975 | 130 307 | −2,23 | 39,55 | −117 666 | 5 153 863 |
2013-10-29 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −3 318 | 133 282 | −2,43 | 39,55 | −131 233 | 5 271 530 |
2013-10-29 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −1 211 | 136 600 | −0,88 | 39,55 | −47 897 | 5 402 735 |
2013-10-29 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −3 191 | 137 811 | −2,26 | 41,09 | −131 118 | 5 662 654 |
2013-10-25 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
A - Award | 234 899 | 234 899 | |||||
2013-10-25 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
A - Award | 25 204 | 141 002 | 21,77 | ||||
2013-10-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 12 000 | −20,00 | 39,88 | −119 647 | 478 589 |
2013-10-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 115 798 | −2,53 | 39,88 | −119 647 | 4 618 302 |
2013-10-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 118 798 | 2,59 | 13,05 | 39 158 | 1 550 611 |
2013-09-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | −3 000 | 15 000 | −16,67 | 39,87 | −119 609 | 598 046 | |
2013-09-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | −10 000 | 0 | −100,00 | 39,87 | −398 676 | ||
2013-09-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 115 798 | −7,95 | 39,87 | −398 676 | 4 616 588 |
2013-09-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | 10 000 | 125 798 | 8,64 | 11,32 | 113 175 | 1 423 719 | |
2013-09-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 115 798 | −2,53 | 39,87 | −119 609 | 4 616 832 |
2013-09-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | 3 000 | 118 798 | 2,59 | 13,05 | 39 158 | 1 550 611 | |
2013-08-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | −3 000 | 18 000 | −14,29 | 42,30 | −126 900 | 761 400 | |
2013-08-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | 42,23 | −422 300 | 422 300 | |
2013-08-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 115 798 | −7,95 | 42,22 | −422 244 | 4 889 501 |
2013-08-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 125 798 | 8,64 | 11,32 | 113 175 | 1 423 719 |
2013-08-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 115 798 | −2,53 | 42,30 | −126 900 | 4 898 255 |
2013-08-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 118 798 | 2,59 | 13,05 | 39 158 | 1 550 611 |
2013-07-30 |
|
4 | CNMD |
CONMED CORP
Sars (Stock Appreciation Rights) |
A - Award | 1 000 | 1 000 | 33,43 | 33 430 | 33 430 | ||
2013-07-30 |
|
4 | CNMD |
CONMED CORP
Rsus (restricted Stock Units) |
A - Award | 3 000 | 3 000 | |||||
2013-07-26 |
|
4 | HAE |
HAEMONETICS CORP
Performance Shares |
A - Award | 50 000 | 50 000 | |||||
2013-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 21 000 | −12,50 | |||
2013-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 20 000 | −33,33 | |||
2013-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 115 798 | −7,95 | 41,88 | −418 820 | 4 849 852 |
2013-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 125 798 | 8,64 | 11,32 | 113 175 | 1 423 719 |
2013-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 115 798 | −2,53 | 41,84 | −125 522 | 4 845 046 |
2013-07-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 118 798 | 2,59 | 13,05 | 39 158 | 1 550 611 |
2013-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 24 000 | −11,11 | |||
2013-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 30 000 | −25,00 | |||
2013-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 115 798 | −7,95 | 41,14 | −411 436 | 4 764 347 |
2013-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 125 798 | 8,64 | 11,32 | 113 175 | 1 423 719 |
2013-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 115 798 | −2,53 | 41,17 | −123 519 | 4 767 763 |
2013-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 118 798 | 2,59 | 13,05 | 39 158 | 1 550 611 |
2013-05-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 27 000 | −10,00 | |||
2013-05-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 40 000 | −20,00 | |||
2013-05-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 115 798 | −7,95 | 38,67 | −386 742 | 4 478 395 |
2013-05-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 125 798 | 8,64 | 11,32 | 113 175 | 1 423 719 |
2013-05-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 115 798 | −2,53 | 38,62 | −115 862 | 4 472 200 |
2013-05-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 118 798 | 2,59 | 13,05 | 39 158 | 1 550 611 |
2013-04-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −488 | 115 798 | −0,42 | 41,83 | −20 413 | 4 843 830 |
2013-04-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −288 | 0 | −100,00 | |||
2013-04-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 50 000 | −16,67 | |||
2013-04-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 116 286 | −7,92 | 41,94 | −419 393 | 4 876 953 |
2013-04-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 126 286 | 8,60 | 11,32 | 113 175 | 1 429 242 |
2013-04-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −288 | 116 286 | −0,25 | 41,94 | −12 079 | 4 876 953 |
2013-04-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 288 | 116 574 | 0,25 | 26,38 | 7 597 | 3 075 222 |
2013-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 288 | −91,24 | |||
2013-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 60 000 | −14,29 | |||
2013-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 116 286 | −7,92 | 41,06 | −410 624 | 4 774 982 |
2013-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 126 286 | 8,60 | 11,32 | 113 175 | 1 429 242 |
2013-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 116 286 | −2,51 | 41,06 | −123 187 | 4 774 982 |
2013-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 119 286 | 2,58 | 26,38 | 79 140 | 3 146 765 |
2013-02-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 3 288 | −47,71 | |||
2013-02-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 70 000 | −12,50 | |||
2013-02-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 116 286 | −7,92 | 41,96 | −419 589 | 4 879 233 |
2013-02-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 126 286 | 8,60 | 11,32 | 113 175 | 1 429 242 |
2013-02-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 116 286 | −2,51 | 41,96 | −125 877 | 4 879 233 |
2013-02-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 119 286 | 2,58 | 26,38 | 79 140 | 3 146 765 |
2013-01-08 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 6 288 | −32,30 | |||
2013-01-08 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 80 000 | −11,11 | |||
2013-01-08 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 116 286 | −7,92 | 41,47 | −414 748 | 4 822 939 |
2013-01-08 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 126 286 | 8,60 | 11,32 | 113 175 | 1 429 242 |
2013-01-08 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 116 286 | −2,51 | 41,47 | −124 424 | 4 822 939 |
2013-01-08 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 119 286 | 2,58 | 26,38 | 79 140 | 3 146 765 |
2012-12-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 9 288 | −24,41 | |||
2012-12-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −10 000 | 90 000 | −10,00 | |||
2012-12-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −10 000 | 116 286 | −7,92 | 40,75 | −407 491 | 4 738 550 |
2012-12-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 10 000 | 126 286 | 8,60 | 11,32 | 113 175 | 1 429 242 |
2012-12-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 116 286 | −2,51 | 40,75 | −122 247 | 4 738 550 |
2012-12-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 119 286 | 2,58 | 26,38 | 79 140 | 3 146 765 |
2012-11-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −1 500 | 6 144 | −19,62 | |||
2012-11-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −5 000 | 50 000 | −9,09 | |||
2012-11-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −1 500 | 58 143 | −2,51 | 81,82 | −122 737 | 4 757 528 |
2012-11-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 1 500 | 59 643 | 2,58 | 52,76 | 79 140 | 3 146 765 |
2012-11-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −5 000 | 58 143 | −7,92 | 81,82 | −409 123 | 4 757 528 |
2012-11-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 5 000 | 63 143 | 8,60 | 22,64 | 113 175 | 1 429 242 |
2012-11-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −534 | 58 143 | −0,91 | 76,33 | −40 762 | 4 438 206 |
2012-11-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −1 463 | 58 677 | −2,43 | 76,33 | −111 675 | 4 478 986 |
2012-10-30 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −1 284 | 60 140 | −2,09 | 78,51 | −100 807 | 4 721 591 |
2012-10-26 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
A - Award | 125 191 | 125 191 | |||||
2012-10-26 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
A - Award | 13 442 | 61 424 | 28,01 | ||||
2012-10-25 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −189 | 47 982 | −0,39 | 78,04 | −14 749 | 3 744 486 |
2012-10-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −1 500 | 7 644 | −16,40 | |||
2012-10-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −5 000 | 55 000 | −8,33 | |||
2012-10-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −5 000 | 48 171 | −9,40 | 80,73 | −403 630 | 3 888 657 |
2012-10-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 5 000 | 53 171 | 10,38 | 22,64 | 113 175 | 1 203 526 |
2012-10-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −1 500 | 48 171 | −3,02 | 80,73 | −121 089 | 3 888 657 |
2012-10-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 1 500 | 49 671 | 3,11 | 52,76 | 79 140 | 2 620 642 |
2012-09-06 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −1 500 | 9 144 | −14,09 | |||
2012-09-06 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −5 000 | 60 000 | −7,69 | |||
2012-09-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −5 000 | 48 171 | −9,40 | 73,67 | −368 374 | 3 548 989 |
2012-09-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 5 000 | 53 171 | 10,38 | 22,64 | 113 175 | 1 203 526 |
2012-09-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −1 500 | 48 171 | −3,02 | 73,70 | −110 550 | 3 550 208 |
2012-09-06 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 1 500 | 49 671 | 3,11 | 52,76 | 79 140 | 2 620 642 |
2012-08-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −1 500 | 10 644 | −12,35 | |||
2012-08-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −5 000 | 65 000 | −7,14 | |||
2012-08-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −5 000 | 48 171 | −9,40 | 71,68 | −358 424 | 3 453 133 |
2012-08-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 5 000 | 53 171 | 10,38 | 22,64 | 113 175 | 1 203 526 |
2012-08-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −1 500 | 48 171 | −3,02 | 71,92 | −107 876 | 3 464 319 |
2012-08-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 1 500 | 49 671 | 3,11 | 52,76 | 79 140 | 2 620 642 |
2012-07-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −1 500 | 12 144 | −10,99 | 74,01 | −111 015 | 898 777 |
2012-07-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 70 000 | −4,11 | 74,02 | −222 048 | 5 181 127 |
2012-07-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 48 171 | −5,86 | 74,02 | −222 048 | 3 565 430 |
2012-07-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 51 171 | 6,23 | 22,64 | 67 905 | 1 158 256 |
2012-07-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −1 500 | 48 171 | −3,02 | 74,01 | −111 015 | 3 565 136 |
2012-07-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 1 500 | 49 671 | 3,11 | 52,76 | 79 140 | 2 620 642 |
2012-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −1 500 | 13 644 | −9,90 | 68,59 | −102 882 | 935 815 |
2012-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 73 000 | −3,95 | 68,47 | −205 412 | 4 998 346 |
2012-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 48 171 | −5,86 | 68,47 | −205 412 | 3 298 292 |
2012-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 51 171 | 6,23 | 22,64 | 67 905 | 1 158 256 |
2012-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −1 500 | 48 171 | −3,02 | 68,59 | −102 882 | 3 303 953 |
2012-06-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 1 500 | 49 671 | 3,11 | 52,76 | 79 140 | 2 620 642 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −1 500 | 15 144 | −9,01 | 71,63 | −107 439 | 1 084 704 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −2 000 | 0 | −100,00 | 71,79 | −143 586 | |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 76 000 | −3,80 | 71,71 | −215 143 | 5 450 279 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 48 171 | −5,86 | 71,71 | −215 143 | 3 454 545 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 51 171 | 6,23 | 22,64 | 67 905 | 1 158 256 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −2 000 | 48 171 | −3,99 | 71,79 | −143 586 | 3 458 341 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 2 000 | 50 171 | 4,15 | 41,15 | 82 300 | 2 064 537 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −1 500 | 48 171 | −3,02 | 71,63 | −107 439 | 3 450 296 |
2012-05-03 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 1 500 | 49 671 | 3,11 | 52,76 | 79 140 | 2 620 642 |
2012-04-09 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
D - Sale to Issuer | X | −167 | 48 171 | −0,35 | 69,69 | −11 638 | 3 356 984 |
2012-04-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −2 000 | 2 000 | −50,00 | 69,76 | −139 521 | 139 521 |
2012-04-04 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 79 000 | −3,66 | 69,81 | −209 426 | 5 514 887 |
2012-04-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 48 338 | −5,84 | 69,81 | −209 426 | 3 374 413 |
2012-04-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 51 338 | 6,21 | 22,64 | 67 905 | 1 162 036 |
2012-04-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −2 000 | 48 338 | −3,97 | 69,76 | −139 521 | 3 372 083 |
2012-04-04 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 2 000 | 50 338 | 4,14 | 41,15 | 82 300 | 2 071 409 |
2012-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −2 000 | 4 000 | −33,33 | 65,80 | −131 600 | 263 200 |
2012-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 82 000 | −3,53 | 65,80 | −197 400 | 5 395 600 |
2012-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 48 338 | −5,84 | 65,80 | −197 400 | 3 180 640 |
2012-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 51 338 | 6,21 | 22,64 | 67 905 | 1 162 036 |
2012-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −2 000 | 48 338 | −3,97 | 65,80 | −131 600 | 3 180 640 |
2012-03-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 2 000 | 50 338 | 4,14 | 41,15 | 82 300 | 2 071 409 |
2012-02-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −2 000 | 6 000 | −25,00 | 65,06 | −130 120 | 390 360 |
2012-02-02 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 85 000 | −3,41 | 65,06 | −195 180 | 5 530 100 |
2012-02-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 48 338 | −5,84 | 65,06 | −195 180 | 3 144 870 |
2012-02-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 51 338 | 6,21 | 22,64 | 67 905 | 1 162 036 |
2012-02-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −2 000 | 48 338 | −3,97 | 65,06 | −130 120 | 3 144 870 |
2012-02-02 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 2 000 | 50 338 | 4,14 | 41,15 | 82 300 | 2 071 409 |
2012-01-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −2 000 | 8 000 | −20,00 | 62,49 | −124 976 | 499 902 |
2012-01-05 |
|
4 | HAE |
HAEMONETICS CORP
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 000 | 88 000 | −3,30 | 62,49 | −187 463 | 5 498 926 |
2012-01-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −3 000 | 48 338 | −5,84 | 62,49 | −187 463 | 3 020 535 |
2012-01-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 3 000 | 51 338 | 6,21 | 22,64 | 67 905 | 1 162 036 |
2012-01-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
S - Sale | X | −2 000 | 48 338 | −3,97 | 62,49 | −124 976 | 3 020 535 |
2012-01-05 |
|
4 | HAE |
HAEMONETICS CORP
Common Stock |
M - Exercise | X | 2 000 | 50 338 | 4,14 | 41,15 | 82 300 | 2 071 409 |